Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
|Articles|January 1, 2002
The American Journal of Managed Care
- January 2002
- Volume 8
- Issue 1
Issues in Pooling Administrative Data for Economic Evaluation
Advertisement
Articles in this issue
almost 25 years ago
TennCare - Medicaid Managed Care in Tennessee in Jeopardyalmost 25 years ago
Effects of Restrictive Formularies in the Ambulatory Care Settingalmost 25 years ago
The Generalist's Patient and the SubspecialistAdvertisement
Related to this article
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.
Bispecific programs differ by practice size, but shared core components can guide adaptation, experts said at a webinar for the Bispecifics Network.
Bipolar disorder often goes undiagnosed for years, and clinicians need to separate mood episodes from normal emotions and keep patients on treatment.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Two machine learning models identifies MASLD in lean adults using 8 routine clinical measurements.
Pharmacists are moving beyond order verification into patient education, adverse effect mitigation, and parts of toxicity triage in bispecific care.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
Elagolix Noninferior to Dienogest for Endometriosis Pain in Phase 3 Trial
3
Kidney Week 2026 Recap: IgAN Advances, Value-Based Care, CKD Care Gaps
4
FAQ: PBM Reform, 340B, and Medicare Shifts Payers Face in 2027
5